Galectin Therapeutics

Yahoo Finance • 25 days ago

Galectin Advances Belapectin Program With FDA Feedback And Secures $10 Million Credit Line

(RTTNews) - Galectin Therapeutics Inc. (GALT) Friday announced that the U.S. FDA has provided written feedback on its development program for Belapectin, the company's investigational galectin-3 inhibitor for patients with MASH cirrhosis a... Full story

Yahoo Finance • 2 months ago

Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update

NORCROSS, Ga., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the thr... Full story

Yahoo Finance • 4 months ago

Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

NORCROSS, Ga., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company management will participate in the H.C. W... Full story

Yahoo Finance • 6 months ago

Freeman buys Galectin therapeutics (GALT) stock worth $14,495

Director Kevin D Freeman acquired 5,000 shares of GALECTIN THERAPEUTICS INC (NASDAQ:GALT) on July 17, 2025, at a price of $2.899 per share, for a total transaction value of $14,495. The purchase comes amid strong momentum, with the stock u... Full story

Yahoo Finance • 6 months ago

Galectin Therapeutics secures $10 million credit line from board chairman

NORCROSS, Ga. - Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical-stage biotech company with a market capitalization of $132 million and currently trading at $2.09, has secured a new $10 million unsecured line of credit from its Board C... Full story

Yahoo Finance • 7 months ago

Galectin Therapeutics stock rating initiated at buy by H.C. Wainwright

H.C. Wainwright initiated coverage of Galectin Therapeutics (NASDAQ:GALT), a $94.3 million market cap company, with a buy rating and a $6.00 price target on Tuesday. The stock has shown strong momentum with an 11% gain over the past week.... Full story

Yahoo Finance • 7 months ago

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension

NORCROSS, Ga., June 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it wil... Full story

Yahoo Finance • 10 months ago

Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update

NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the ye... Full story

Yahoo Finance • 2 years ago

UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the thr... Full story

Yahoo Finance • 2 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the thr... Full story

Yahoo Finance • 2 years ago

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD

Pharmacokinetics and safety of belapectin in patients with hepatic insufficiencyLack of impact of belapectin on cardiac repolarization (QT interval)Very High Elevation of Gamma-Glutamyl Transpeptidase (GGT) as a new marker of disease progr... Full story

Yahoo Finance • 2 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023

NORCROSS, Ga., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 7th... Full story

Yahoo Finance • 2 years ago

Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors

NORCROSS, Ga., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today that Dr. Benjamin S. Carson, Sr. has been nominated to serve... Full story

Yahoo Finance • 2 years ago

Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis

NORCROSS, Ga., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today reported the positive outcome of its fourth data and safety monitoring board... Full story

Yahoo Finance • 2 years ago

Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023

NORCROSS, Ga., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today announced it will participate in the 20th edition of the Discovery on Targe... Full story

Yahoo Finance • 2 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023

NORCROSS, Ga., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 25... Full story

Yahoo Finance • 2 years ago

Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023

NORCROSS, Ga., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will participate in the 9th Edition of the Pari... Full story

Yahoo Finance • 2 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update

NORCROSS, Ga., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the thr... Full story

Yahoo Finance • 3 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update

NORCROSS, Ga., May 15, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the thre... Full story

Yahoo Finance • 3 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023

NORCROSS, Ga., April 27, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright Bi... Full story